Lipid and Renal Profile in Assessing the Severity of Alcoholic Liver Disease

Overview

Journal Bioinformation

Specialty Biology

Date 2023 Sep 1

PMID 37654846

Authors

Chitrasivasankari G

Gomathi V

Nachiappan R

Gurumoorthy Kaarthikeyan

Mahalakshmi S

Affiliations

Soon will be listed here.

Abstract

Lipid and Renal dysfunction in Alcoholic liver disease (ALD) patients occurs either due to multi-organ involvement or secondary to alcoholism. This study was conducted to evaluate the role of lipid and renal parameters in assessing the severity of progression of ALD. Sixty cases of ALD (two groups based on compensated and decompensated features) and thirty healthy controls for comparison were included. Lipid profile (Total Cholesterol, LDL, HDL and Triglycerides) and renal parameters (serum urea, creatinine and uric acid), total and direct bilirubin, total protein and albumin were measured using automated chemistry analyzer. There was a significant decrease in Total cholesterol ,LDL and HDL levels and increased triglycerides when compared to controls (mean of 128.4 ± 59 vs 155 ± 27.2, 77 ± 44.3 vs 97.4 ± 27.2, 28.3 ± 18 vs 39.5 ± 14.1 and 115.8 ± 70.4 vs 91 ± 38 mg/dL respectively). Lipid profile showed a linear decrease while progressing from compensated to decompensated ALD. Renal parameters revealed a statistically significant decrease in serum urea ,increased creatinine and uric acid levels when compared to controls (17.57±2.96 vs23.73±4.94, 1.12±0.55 vs0.88±0.16,6.60±1.32 vs 4.68±1.40 mg/dL respectively).Total cholesterol and HDL showed a linear decrease when ALD progresses. Serum uric acid showed an early increase in compensated stage of ALD. This study inferred that Total cholesterol, TGL, HDL and uric acid can be used for assessing the severity of progression of ALD.

References

Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P . Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 2010; 30(7):937-47. DOI: 10.1111/j.1478-3231.2010.02272.x. View

Corrao G, Ferrari P, Zambon A, Torchio P . Are the recent trends in liver cirrhosis mortality affected by the changes in alcohol consumption? Analysis of latency period in European countries. J Stud Alcohol. 1997; 58(5):486-94. DOI: 10.15288/jsa.1997.58.486. View

Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C . A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33(2):464-70. DOI: 10.1053/jhep.2001.22172. View

Das S, Vasudevan D . Biochemical diagnosis of alcoholism. Indian J Clin Biochem. 2012; 20(1):35-42. PMC: 3454181. DOI: 10.1007/BF02893039. View

Gines P, Schrier R . Renal failure in cirrhosis. N Engl J Med. 2009; 361(13):1279-90. DOI: 10.1056/NEJMra0809139. View

Tsochatzis E, Bosch J, Burroughs A . Liver cirrhosis. Lancet. 2014; 383(9930):1749-61. DOI: 10.1016/S0140-6736(14)60121-5. View

Gao B, Xiao J, Zhang M, Zhang F, Zhang W, Yang J . High-density lipoprotein cholesterol for the prediction of mortality in cirrhosis with portal vein thrombosis: a retrospective study. Lipids Health Dis. 2019; 18(1):79. PMC: 6441144. DOI: 10.1186/s12944-019-1005-8. View

Marsano L, Mendez C, Hill D, Barve S, McClain C . Diagnosis and treatment of alcoholic liver disease and its complications. Alcohol Res Health. 2004; 27(3):247-56. PMC: 6668876. View

Mendez-Sanchez N, Almeda-Valdes P, Uribe M . Alcoholic liver disease. An update. Ann Hepatol. 2005; 4(1):32-42. View

10.

MacSween R, Burt A . Histologic spectrum of alcoholic liver disease. Semin Liver Dis. 1986; 6(3):221-32. DOI: 10.1055/s-2008-1040605. View

11.

Cheng Z, Lv Y, Pang S, Bai R, Wang M, Lin S . Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. Acta Pharm Sin B. 2015; 5(3):194-200. PMC: 4629233. DOI: 10.1016/j.apsb.2015.02.003. View

12.

Rehm J, Shield K . Global Burden of Alcohol Use Disorders and Alcohol Liver Disease. Biomedicines. 2019; 7(4). PMC: 6966598. DOI: 10.3390/biomedicines7040099. View

13.

Slack A, Yeoman A, Wendon J . Renal dysfunction in chronic liver disease. Crit Care. 2010; 14(2):214. PMC: 2887107. DOI: 10.1186/cc8855. View

14.

Lefkowitch J . Morphology of alcoholic liver disease. Clin Liver Dis. 2005; 9(1):37-53. DOI: 10.1016/j.cld.2004.11.001. View

15.

Das S, Nayak P, Vasudevan D . Biochemical markers for alcohol consumption. Indian J Clin Biochem. 2012; 18(2):111-8. PMC: 3453888. DOI: 10.1007/BF02867376. View